A Compound Defined by a Single Research Lab
BPC-157 research originates almost entirely from the Sikiric laboratory at the University of Zagreb, which has published hundreds of papers spanning multiple tissue systems over roughly three decades. No other research peptide of comparable duration has such a concentrated literature origin — which is both its strength and a factor worth understanding.
The research-grade compound is available as BPC-157 10mg.
Structure: A Pentadecapeptide From Gastric Juice
BPC-157 is a 15-amino-acid fragment isolated from a larger gastric protective protein in human gastric juice. The synthetic pentadecapeptide reproduces this sequence and shows stability in gastric fluid — an unusual property for a research peptide and the reason oral delivery has been studied at all.
Key Mechanistic Findings
- Nitric oxide system engagement: Interaction with endothelial nitric oxide synthase, modulating vascular responses
- VEGFR2 signaling: Involvement in angiogenic tissue repair — forming new vasculature during wound healing research
- Growth hormone receptor upregulation: Secondary effect that may support the compound's broader repair profile
- Dopaminergic and serotonergic modulation: CNS effects studied in the Sikiric inflammation models
Tissue Systems Studied
The Sikiric literature spans:
- GI mucosa — the originally published system
- Tendon and ligament — rat Achilles transection research
- Bone — fracture healing studies
- Skin — wound closure models
- CNS — neuroprotection research in stroke models
- Cardiovascular — endothelial response studies
The breadth is notable — and is the reason BPC-157 shows up in so many adjunct-research contexts.
Oral vs Subcutaneous Delivery Research
BPC-157's gastric stability has enabled oral research protocols — unusual for a peptide. The comparative literature suggests the subcutaneous route produces more predictable systemic exposure; the oral route produces effects more concentrated in the GI system. Research design should select based on the target tissue.
Pairing With Other Research Compounds
BPC-157 is frequently paired with TB-500 in broader tissue-repair protocols. The mechanisms are non-overlapping — BPC-157 engages the NO and VEGFR2 systems while TB-500 targets G-actin dynamics and has its own VEGF interactions — so co-study covers a wider repair pathway set.
Research Sourcing
Quality controls that matter for BPC-157 specifically: >98% HPLC purity, third-party test reports, lyophilized form, and stability-validated handling. See BPC-157 10mg for the standard research vial.